Log in or Sign up for Free to view tailored content for your specialty!
Stomach/Duodenum News
Investigation links Salmonella outbreak to pet bearded dragons
An investigation into a Salmonella outbreak in Canada linked to pet bearded dragons revealed a multinational outbreak that included a dozen cases in the United States in 2021 and 2022, researchers reported.
Salmonella cases double as CDC expands warning on charcuterie meats
The CDC expanded its warning on eating charcuterie meats after the number of cases in a multistate Salmonella outbreak doubled over the last 2 weeks.
Log in or Sign up for Free to view tailored content for your specialty!
Perceived stress, gastrointestinal factors linked to menopause symptoms
Perceived stress and certain gastrointestinal factors were linked to menopausal symptoms, with reproductive stages, physical activity, BMI and previously diagnosed depression or anxiety affecting symptom severity, researchers reported.
Joint statement calls for FDA to require drug trials to include people with obesity
Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.
Tirzepatide earns FDA approval for obesity treatment
The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.
Vagal nerve stimulation reduces need for rescue medication in gastroparesis, dyspepsia
VANCOUVER, British Columbia — As-needed vagal nerve stimulation reduced rescue mediation use among patients with nausea related to gastroparesis or functional dyspepsia, according to data presented at the ACG Annual Scientific Meeting.
FDA grants MR conditional use to Enterra’s electrical stimulation device for gastroparesis
The FDA has granted conditional use with magnetic resonance imaging to Enterra Medical’s implantable electrical stimulation device for management of symptoms associated with gastroparesis, according to a company release.
Tirzepatide 15 mg is the ‘most efficacious’ for weight loss among GLP-1 agonists
VANCOUVER, British Columbia — Tirzepatide 15 mg was associated with the highest degree of weight loss compared with other glucagon-like peptide-1 agonists and placebo, according to a presenter at the ACG Annual Scientific Meeting.
Apraglutide reduces parenteral support needs in patients with short bowel syndrome
Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.
Larger HbA1c drop in type 2 diabetes treated with semaglutide vs. other GLP-1 agents
Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read